KemPharm (NASDAQ:KMPH) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.17), Morningstar.com reports.
Shares of NASDAQ:KMPH traded down $0.06 on Friday, reaching $2.56. The company had a trading volume of 190,097 shares, compared to its average volume of 398,779. KemPharm has a 52-week low of $2.00 and a 52-week high of $8.40. The company has a market capitalization of $41.87 million, a PE ratio of -0.86 and a beta of 0.86.
A number of brokerages have weighed in on KMPH. Oppenheimer set a $11.00 target price on KemPharm and gave the company a “buy” rating in a research report on Wednesday, October 31st. Zacks Investment Research raised KemPharm from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Tuesday, September 25th. CIBC reiterated an “outperform” rating on shares of KemPharm in a report on Friday, September 21st. ValuEngine downgraded KemPharm from a “buy” rating to a “hold” rating in a report on Tuesday, September 4th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $11.00 price target on shares of KemPharm in a report on Tuesday, August 14th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $10.50.
Hedge funds have recently made changes to their positions in the stock. Cowen Inc. purchased a new position in KemPharm during the 2nd quarter worth $2,381,000. Millennium Management LLC grew its stake in KemPharm by 878.0% during the 2nd quarter. Millennium Management LLC now owns 151,250 shares of the specialty pharmaceutical company’s stock worth $983,000 after buying an additional 135,784 shares during the last quarter. Royal Bank of Canada grew its stake in KemPharm by 1,847.1% during the 1st quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 22,886 shares during the last quarter. Renaissance Technologies LLC grew its stake in KemPharm by 101.1% during the 2nd quarter. Renaissance Technologies LLC now owns 181,800 shares of the specialty pharmaceutical company’s stock worth $1,182,000 after buying an additional 91,400 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in KemPharm during the 2nd quarter worth $176,000. Hedge funds and other institutional investors own 39.28% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first reported by BBNS and is the property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/2018/11/10/kempharm-kmph-announces-earnings-results/2973735.html.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Recommended Story: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.